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Abstract
Determination of CXCR4-usage patterns is essential in establishing suit-
ability of CCR5 antagonist prescription in HIV-1 infected individuals to
prevent treatment failure. Previous studies have suggested a switch to
CXCR4-usage to be far less common in subtype C, yet recent studies
have reported between 30 - 50% CXCR4-usage in this subtype. How-
ever, CXCR4-usage in subtype C is poorly characterised. Furthermore,
the reliability of available genotypic algorithms is unknown for subtype C
sequences.
In this study, a comparative analysis of the predictive ability of several
subtype B-modeled genotyping algorithms in subtype C tropism determi-
nation was undertaken. A total of 731 HIV-1 subtype C V3 sequences with
phenotypically determined coreceptor tropism were collated from several
sources. Datasets of 349 CCR5, 25 CXCR4 exclusive and 31 R5X4 (Dual)
sequences were submitted to 11 various tropism prediction tools. The best
performing tool was used to determine the tropism of 12,121 subtype C V3
sequences with unknown phenotypes, in order to characterise the preva-
lence and method of CXCR4 usage in HIV-1 subtype C.
We determined that geno2pheno with a false positive rate of 5% is the best
approach for predicting CXCR4-usage in subtype C sequences with an
accuracy of 94% (89% sensitivity and 99% specificity). Contrary to what
has been reported for subtype B, the optimal approaches for prediction
of CXCR4-usage in sequence from viruses that use CXCR4 exclusively,
also perform best at predicting CXCR4-use in dual-tropic viral variants.
Furthermore, we find that a switch to CXCR4 usage is seen in subtype C
for well over 20 years and has occurred consistently over time. At 5%, the
frequency of CXCR4-usage in subtype C database records is lower than
previous reports for both subtype C and B.
The Geno2pheno coreceptor tool may be used as a reliable genotypic pre-
dictor in clinical settings to establish the viability of CCR5-antagonist
therapies using drugs such as Maraviroc and provides a rapid and cost
effective alternative to phenotypic testing in resource limited areas. A
 
 
 
 
switch to CXCR4-usage in subtype C is constant but lower when com-
pared to subtype B, a finding which may have broad implications for the
design of intervention and treatment strategies for HIV-1 subtype C.
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Chapter 1
Introduction
1.1 General Background
No single factor has had a more devastating impact on modern society than the spread
of the Human Immunodeficiency Virus (HIV). The number of HIV infections has
reached epidemic proportions, with an estimated 34 million people living with HIV
globally by the end of 2011 (UNAIDS, 2013). It is estimated that 2.5 million people
were newly infected with this virus in 2011 (UNAIDS, 2013). HIV is the etiologi-
cal agent responsible for the development of Acquired Immune Deficiency Syndrome
(AIDS), which has been attributed to over 25 million deaths globally since it was first
discovered 30 years ago (UNAIDS, 2013). In 2011 alone, it was estimated that 1.7
million adults and children died from this disease (UNAIDS, 2013).
The highest prevalence of HIV infections are in developing countries, with the
highest incidences occurring in Africa, Central Asia, Eastern Europe and the Caribbean
(Figure 1.1) (UNAIDS, 2013). However, the effects of this virus are most severe in
Sub-Saharan Africa, where 69% of all people living with HIV reside, and the number
of people living with HIV in the region was estimated to be 23.5 million (UNAIDS,
1
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1. INTRODUCTION
2013). Of the countries in this region, South Africa has an estimated 5.6 million people
living with HIV - more than any other country in the world. In spite of these alarm-
ing figures and the dire need to curb the spread of this deadly virus, our knowledge
of basic HIV etiology, such as mode of coreceptor usage, is incomplete, limiting our
ability to effectively design suitable treatments. As a result, the death toll associated
with this disease continues to rise globally, particularly in Africa, where AIDS is the
most common cause of death (UNAIDS, 2013).
The first documented reports of AIDS occurred in 1981, when young, previously
healthy homosexual males in the Unites States presented with a series of rare diseases
and opportunistic infections (CDC, 1981, 1982a,b, 2006). The interconnected nature
of these cases soon became evident, and in 1982 the term AIDS was coined by the
Centre for Disease Control and Prevention (CDC) to describe this disease which was
spread primarily through sexual contact, blood products and through breast feeding.
Although little was known about the etiology of the disease, it was characterized
by a decrease in the CD4+ helper/inducer subset of T lymphocyte cells, leading to a
suppressed immune response, and which in turn resulted in an array of opportunistic
infections (CDC, 1982a). In 1983, a link was established between the AIDS seen in
macaque monkeys and that seen in humans, and it was suggested that an infectious
agent such as a virus might be the cause of the disease in humans as it was in the
primates (Hunt et al., 1983). Later in that same year, the retrovirus termed Human
Immunodeficiency Virus (HIV) was established to be the definitive etiologic agent of
AIDS (Barre´-Sinoussi et al., 1983; Gallo et al., 1983).
3
 
 
 
 
1. INTRODUCTION
1.2 Origins of HIV
Human infection by HIV is a consequence of cross species transmission of simian im-
munodeficiency virus (SIV) from non-human primates (Robertson et al., 1995; Sharp
and Hahn, 2011; Hahn et al., 2000; Lemey et al., 2003). Based on the SIV strain that
it is derived from, HIV has been classified into two groups: HIV-1 and HIV-2, each
of which have arisen through independent zoonotic events (Gao et al., 1999; Tebit and
Arts, 2011; Wertheim and Worobey, 2009).
Human Immunodeficiency Virus type 2 (HIV-2) is believed to have arisen in Guinea
Bissau in the early 1930s (Tebit and Arts, 2011; Lemey et al., 2003), through a sooty
mangaby transmission event (SIVsmm). This strain of HIV, which is less easily trans-
mitted is now primarily restricted to western Africa (Lemey et al., 2003), and is re-
sponsible for roughly 1% of all HIV infections (Lemey et al., 2003; Marlink et al.,
1994).
By contrast, Human Immunodeficiency Virus type 1 (HIV-1) infections have be-
come pandemic, with 99% of the global HIV infections caused by this viral strain
(Lemey et al., 2003; Marlink et al., 1994). Studies indicate that HIV-1 arose in the
West Central African forests of Cameroon and the Democratic Republic of Congo in
the early 1900s (Tebit and Arts, 2011; Santiago et al., 2002; Gao et al., 1999; Keele
et al., 2006). The origin of this highly virulent stain of HIV has been traced back to
SIVcpz infected chimpanzees (Pan troglodytes troglodytes) (Gao et al., 1999).
4
 
 
 
 
1. INTRODUCTION
1.3 Classification
The Human Immunodeficiency Virus is characterized by extensive genetic hetero-
geneity, driven by several factors, including recombination events during replication
(Temin, 1993), lack of proof-reading ability of the reverse transcriptase (RT) (Roberts
et al., 1988; Preston et al., 1988; Temin, 1993), the high replication rate of HIV-1 in
vivo (Ho et al., 1995), and host selective immune pressures (Michael, 1999; Preston
and Dougherty, 1996; Preston et al., 1988; Ho et al., 1995; Wei et al., 1995; Roberts
et al., 1988). As a result of this variability, HIV-1 viruses have been divided into several
distinct genetic groups: group M (main), group O (outlier), and group N (non-M/ non-
O). Group P (Pending identification of further human cases) was recently described
and subsequently confirmed as the fourth group, having being found in two unrelated
patients of Cameroonian origin (Plantier et al., 2009; Vallari et al., 2011). Phylogenetic
evidence suggests that this HIV-1 group is most closely related to a strain of SIV de-
rived from gorillas (SIVgor) than it is to any of the other groups (Figure 1.2) (Plantier
et al., 2009; Vallari et al., 2011).
Of these, Group M contributes to the greatest phylogenetic diversity among all
groups and is responsible for over 95% of global HIV isolates (Vidal et al., 2000;
Hahn et al., 2000; Ward et al., 2013). As determined by the analysis of complete viral
genomes, group M is divided into nine distinct subtypes (A-D, F-H, J and K), with
each phylogenetically associated clade denoting a distinct lineage of HIV and having
a different geographical distribution (Robertson et al., 2000). Within a single subtype,
viral isolates may display nucleotide distances of up to 35% (Subbarao and Schochet-
man, 1996). Furthermore, depending on the gene analysed genetic variation between
5
 
 
 
 
1. INTRODUCTION
Figure 1.2: Phylogenetic clustering of HIV-1 groups M, N, O and P derived from nu-
cleotide alignment of genome sequences, showing group P clustering closely together
on a branch shared with the SIVgor strains. Source: http://jvi.asm.org/content/85/3/
1403/F2.expansion.html
6
 
 
 
 
1. INTRODUCTION
subtypes can range from 30 - 40% (Rotta and Almeida, 2011; Moore et al., 2001). Ge-
netic recombination between multiple subtypes of HIV circulating within an individual
has given rise to a further 58 unique circulating recombinant forms (CRF) of the virus
within Group M (Han et al., 2013).
Subtype C is the most prevalent subtype, accounting for almost 60% of all HIV
cases, and representing 22 million infections globally (UNAIDS, 2013). It is the most
rapidly spreading form of HIV-1, with the highest number of infections occurring in
developing countries such as those in East and Southern Africa, as well as India, Nepal
and parts of China (Goudsmit, 1997). Despite the major role this subtype plays in shap-
ing the epidemic, the vast majority of HIV research is centered on HIV-1 subtype B,
which is primarily found in Europe, the Americas and Oceania where the majority of
HIV research is financed and conducted (Paga´n and Holguı´n, 2013). However, world-
wide subtype B accounts for approximately 12% of all HIV infections (Goudsmit,
1997).
1.4 HIV Replication Cycle
HIV-1 infects cells of the CD4+ T-cell and macrophage lineages and takes between 48
and 72 hours to complete a single replication cycle (McDougal et al., 1986; Moham-
madi et al., 2013). The HIV replication cycle can be divided into an early and a late
phase, based on the order of events taking place (Freed, 2001).
The early phase of the HIV life cycle begins with the binding of the viral dock-
ing glycoprotein gp120 to the primary host cell receptor, CD4, triggering a series of
7
 
 
 
 
1. INTRODUCTION
conformational changes. These structural changes allow chemokine receptor binding
to take place and subsequently, fusion of the viral and cellular membranes (Figure1.3
Steps 1-3) (Sattentau and Moore, 1991; Bergeron et al., 1992). This entry process is
described in more detail in section 1.7 of this chapter.
Once membrane fusion has taken place, the HIV core containing the viral genome
is released into the cytoplasm of the target cell, along with viral proteins (Freed, 2001;
Weber, 2001; Coiras et al., 2009). The two single stranded viral RNA molecules are
then retrotranscribed into linear double stranded proviral cDNA by the viral enzyme
reverse transcriptase, and is subsequently known as the reverse transcription complex
(RTC) (Figure 1.3 Step 4) (Freed, 2001; Weber, 2001; Coiras et al., 2009). Prior to
nuclear integration, uncoating of the capsid takes place, followed by the formation
of the RTC, (McDougal et al., 1986; Temin, 1993). A large nucleoprotein complex
or pre-integration complex (PIC) consisting of viral and cellular proteins surrounding
the viral genetic material is assembled (Miller et al., 1997; Coiras et al., 2009). The
PIC is translocated from the host cell periphery towards the nucleus via microtubules
and actin filaments, where nuclear import takes place through a nuclear pore complex
(Miller et al., 1997; Ross and Cullen, 1998). The viral DNA is then integrated into the
host cell genome by integrase (IN), and transfer of the modified provirus DNA into the
host genome takes place (Figure 1.3 Step 5), completing the early phase of the repli-
cation cycle (Chiu and Davies, 2004).
Although the host cellular machinery is used by the HIV proviral insert for repli-
cation, the synthesis of viral RNA and proteins is strictly controlled by viral regulatory
proteins in a process known as transcription (Wu and March, 2003) (Figure 1.3 Step
8
 
 
 
 
1. INTRODUCTION
Figure 1.3: Life cycle of the Human Immunodeficiency Virus. Source: http://stanford.
edu/⇠rabriggs/hiv/lifecycle.jpg
9
 
 
 
 
1. INTRODUCTION
6). This Viral transcriptome is able to encode for all necessary viral proteins, with the
early viral proteins, Tat and Rev, regulating the expression of the late viral proteins, the
structural and accessory proteins (Wu and March, 2003). Newly produced viral pro-
teins and the RNA genome assemble in the cytoplasm at the cell membrane (Figure 1.3
Step 7), where processed Env is expressed and new virus particles will form (Briggs
et al., 2009). The final step of the virus life cycle includes budding from infected cells
(Figure 1.3 Step 8 and 9), followed by viral protease processing of Gag and Gag-Pol
precursors to form mature infectious particles (Briggs et al., 2009) (Figure 1.3 Step
10).
1.5 Viral Genome Organisation
HIV and SIV are members of the Lentivirus genus of the Retroviridae family. Retro-
viridae are enveloped viruses that are composed of two identical positive-sense RNA
strands and are characterised by the ability to reverse transcribe RNA into DNA dur-
ing viral replication (Freed, 2001). The HIV-1 genome is approximately 9.8 kilobases
and, when integrated as a double stranded DNA (provirus), is flanked by long terminal
repeats (LTR) generated during reverse transcription (Freed, 2001).
The HIV genome consists of several unique genes encoding regulatory proteins.
These include Tat and Rev, as well as the accessory proteins Nef, Vif, Vpr, and Vpu
(Figure 1.4). These genes are important regulators of viral replication, transcription
and assembly (Wei et al., 1995; Weber, 2001; Doehle et al.). In addition to gene prod-
ucts, the retroviral genome also contains structural regulatory motifs, such as the trans-
active response element (TAR) and Rev response element (RRE), which are required
10
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1. INTRODUCTION
for transcription and export of non-spliced and partially spliced viral mRNAs to the
cytoplasm (Wei et al., 1995; Weber, 2001).
The genomic RNA contains three open reading frames and encodes the group-
specific antigen (gag), polymerase (pol), and envelope (env) genes (Figure 1.4). These
three primary structural gene products are initially synthesized as polyprotein precur-
sors, which are then processed by viral or cellular proteases into viral proteins (Wei
et al., 1995; Weber, 2001). The gag gene encodes the Gag polyprotein precursor p55
that is cleaved by the viral protease into matrix (MA), capsid (CA), nucleocapsid (NC)
and Vpr-binding proteins (McDougal et al., 1986). The viral enzymes protease (PR),
integrase (IN), RNAse H and reverse transcriptase (RT) are encoded by the pol gene
and are initially produced as a Gag-Pol precursor and processed by the viral protease
(McDougal et al., 1986). The env gene encodes the polyprotein precursor gp160, which
is produced intracellularly through enzymatic addition of complex carbohydrates to the
synthesised protein (Ross and Cullen, 1998) (Figure 1.4). The gp160 molecule is pro-
teolytically cleaved by host cellular enzymes, forming the gp120 and gp41 proteins
(Chan et al., 1997). The gp120 protein lies on the external surface of the viral particle,
while the gp41 protein is located internally and is attached to it across the membrane,
together forming a non-covalent transmembrane complex. Fusion of the cellular and
viral membranes is mediated by the gp41 component of the transmembrane complex,
resulting in the formation of a pore which allows virion genetic material to pass into
the cell.
12
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1.6 Structure of gp120
Three gp120s bound as heterodimers to a transmembrane glycoprotein gp41, form a
trimer complex on the surface of a HIV virion - called the envelope spike (Liu et al.,
2008). To enable cell entry by HIV, the gp120 glycoprotein, must first be recognized
by, and bind to a CD4 receptor on the target host cell (Dalgleish et al., 1984; Maddon
et al., 1986; McDougal et al., 1986). This binding induces a conformational change in
the gp120/gp41 trimer complex (Sattentau and Moore, 1991; Liu et al., 2008) thereby
enabling binding of a chemokine receptor. In vivo, these coreceptors may be either
CCR5 or CXCR4, and in some instances, both coreceptors can be used for cell entry
(Dragic et al., 1996).
Gp120 amino acid sequences consist of five relatively conserved regions (C1 – C5)
alternating with five variable regions (V1 – V5) (Starcich et al., 1986; Chan et al.,
1997). The conserved regions form the protein core, which has an inner and an outer
domain formed by secondary folding structures, while the variable regions are known
to form loops which are anchored to the core via cysteine disulphide bonds (Kwong
et al., 1998; Liu et al., 2008). Attached to the outer domain of the gp120 core as well
as within the loops, are a series of complex, host derived sugars, forming a glycan
shield around the protein (Quin˜ones-Kochs et al., 2002; Polzer et al., 2002). Apart
from maintaining env structure, the heavily glycosylated nature of gp120 is important
in the occlusion of neutralising antibody epitopes and receptor binding sites (Kwong
et al., 1998; Wyatt et al., 1998; Quin˜ones-Kochs et al., 2002; Pollakis et al., 2001).
13
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1.7 HIV-1 Cell Entry
The entry of an HIV particle into the target cell involves an intricate series of sequential
interactions, the primary stages of which are: (i) attachment of the viral gp120 to the
CD4 receptor, (ii) binding of the gp120 to either of the co-receptors CCR5 or CXCR4
and (iii) fusion of the viral and cellular membranes.
1.7.1 CD4 Binding
The CD4 glycoprotein, expressed on the surface of macrophages, T-cells, monocytes,
and dendritic cells, is the primary receptor involved in HIV infection and host cell
entry (Chan et al., 1997). Cellular entry is brought about by strong electrostatic and
molecular interactions between several gp120s and several CD4 proteins. This binding
induces a conformational change in the gp120/gp41 trimer complex (Sattentau and
Moore, 1991; Liu et al., 2008), subsequently leading to the exposure of the coreceptor
binding sites. Thereafter, a gp41 fusion peptide is inserted into the host cell membrane
(Buzon et al., 2010).
1.7.2 Coreceptor Usage
CCR5-tropic viruses are associated with primary transmission and can persist through-
out infection (Dragic et al., 1996; Alkhatib, 2009). In as many as 50% of HIV-1 sub-
type B infections, a switch to CXCR4-usage has been observed and this switch is gen-
erally regarded as an indicator of disease progression (Koot et al., 1993; Hazenberg
et al., 2003; Levine and Sodora, 2006). Early studies of HIV-1 subtype C suggested
that a switch to CXCR4-usage was less common in subtype C compared to subtype B
(Abebe et al., 1999; Pollakis et al., 2004), however more recent studies have suggested
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that between 30-50% of subtype C infected individuals exhibit a change to CXCR4-
usage during disease progression (Connell et al., 2008; Kassaye et al., 2009; Michler
et al., 2008; Cilliers et al., 2003; Papathanasopoulos et al., 2002; Johnston et al., 2003).
Dual-tropic viruses (R5X4) capable of using either CCR5 or CXCR4 for host cell
entry have been described (Berger et al., 1998; Alkhatib, 2009) as have dual-tropic
viruses that, while capable of using either receptor for cell entry, exhibit preferential
use of either CCR5 (dual-R) or CXCR4 (dual-X) (Huang et al., 2007, 2009). Detect-
ing the presence of dual-tropic viruses in an individuals viral population is difficult
however, as a mixed population of R5 and X4 viruses will be identified as dual in a
population-based phenotyping assay.
1.7.3 Cell Membrane Fusion
Once coreceptor binding has taken place, a second conformational shift occurs in the
gp120/gp41 trimer complex, enabling the fusion of viral and cellular membranes (Sat-
tentau and Moore, 1991; Bergeron et al., 1992). The viral and cellular membranes
are brought near each other following the formation of a six-helix bundle of the gp41
ectodomain (Weissenhorn et al., 1997; Chan et al., 1997; Chan and Kim, 1998). An in-
termediate bridging state is created when the gp41 fusion peptide is exposed to the cell
membrane, enabling for fusion to occur and the subsequent transfer of viral genetic
material to the host cell (Buzon et al., 2010).
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1.8 HIV-1 Tropism Nomenclature
Although several chemokine receptors are found to enable cell entry in a laboratory
setting, in vivo, HIV-1 viruses are capable of using only the CCR5 or CXCR4 recep-
tors (Doms and Trono, 2000). The following nomenclature, based on potential viral
coreceptor usage patterns, is currently used to describe viral tropism (Berger et al.,
1998, 1999):
• CCR5-tropic: Viruses or virus populations that are only able to use the CCR5
chemokine co-receptor to infect CD4+ cells. They are typically referred to as R5
viruses.
• CXCR4-tropic: Viruses or virus populations that are only able to use the CXCR4
chemokine co-receptor to infect CD4+ cells. They are typically referred to as X4
viruses.
• Dual (D)-tropic: Viruses or virus populations that are able to use either the
CCR5 or CXCR4 co-receptors to infect CD4+ cells.
The term CXCR4-using (as used throughout this thesis) is often used to broadly
refer to all HIV viruses capable of using the CXCR4 coreceptor for cell entry, and in-
cludes both viral strains using the CXCR4 coreceptor exclusively as well as dual tropic
viruses (Kiselyeva et al., 2007). The assays commonly used in a clinical setting are not
capable of distinguishing between dual tropic viruses and mixed viral populations con-
taining both R5- and X4-using strains (Huang et al., 2007, 2009).
16
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1.9 Tropism Determination
Determining the coreceptor usage profile of an individuals viral population has been
used as an indicator of disease progression (Connor et al., 1997; Verhofstede et al.,
2012; Zhang et al., 1998). In more recent years it has been used as an approach for
detecting resistance to CCR5 antagonists (Cilliers et al., 2003; Westby and van der
Ryst, 2005; Doranz et al., 1997). The approval of the first CCR5 antagonist, maraviroc
(Selzentri R ), has sparked the need for HIV coreceptor determination in the clinical
setting (Poveda et al., 2006, 2009; Collins and iBase, 2007). Treatment with maravi-
roc essentially mimics the CCR5  32 phenotype in that it blocks the CCR5 receptor,
making it unavailable for binding (Baba et al., 1999). This 32bp deletion mutation in
the CCR5 receptor – seen in about 4-15% of Europeans (Hummel et al., 2005) – con-
fers immunity to homozygous carriers and a delay in disease progression to individuals
with a heterozygous deletion, as HIV is unable to use this receptor to gain cell entry
(Huang et al., 1996; Baba et al., 1999; Lederman et al., 2006). Since CCR5 antago-
nists are ineffective against CXCR4-using viral populations, it is essential for HIV-1
coreceptor to be determined before the onset of treatment.
1.9.1 Phenotypic methods
To date, phenotypic assays are the most effective means of elucidating the corecep-
tor tropism of a viral population (Fouchier et al., 1992). Monogram Biosciences
TrofileTMassay (Whitcomb et al., 2007) which is based on recombinant virus tech-
nology, has been the most widely used diagnostic test, given that it was the only as-
say which provided tropism information in the maraviroc clinical trials (Poveda et al.,
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2010). Phenotypic approaches such as this however, are expensive, laborious, time
consuming and unavailable for routine use in all laboratories, especially for use in de-
veloping counteries (Prosperi et al., 2010; Sierra et al., 2007). Thus, bioinformatics
approaches based on viral genotyping have been suggested to be a viable alternative
for routine coreceptor tropism testing (McGovern et al., 2010).
1.9.2 Genotypic methods
Genotypic tropism testing is currently accepted as a standard for tropism determination
according to the European, British and GermanAustrian guidelines for tropism testing,
and is routinely used in the clinical setting (Vandekerckhove et al., 2010, 2011a,b).
While many amino acid positions throughout gp120 have been suggested to influence
coreceptor affinity and tropism (Rizzuto and Sodroski, 2000; Rizzuto et al., 1998; Boyd
et al., 1993; Bergeron et al., 1992; Ross and Cullen, 1998; Hoffman et al., 2002; Naba-
tov et al., 2004), the V3 loop appears to be the strongest determinant of coreceptor
tropism with amino acid mutations affecting V3 net charge, charge at positions 11, 24
and 25 and glycan binding patterns all implicated in causing a switch from CCR5- to
CXCR4-usage (Clevestig et al., 2006; Pollakis et al., 2001; Polzer et al., 2002; Fouch-
ier et al., 1992; Cardozo et al., 2007; Resch et al., 2001).
Early genotypic algorithms predicted the coreceptor tropism of HIV-1 V3 sequences
using the properties of the amino acids at positions 11 and 25 while later algorithms
account for various properties of the entire V3 loop (Fouchier et al., 1992; Cardozo
et al., 2007; Jensen et al., 2003, 2006; Sing et al., 2007a; Pillai et al., 2003; Cormier
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and Dragic, 2002; Poveda et al., 2010). With the exception of C-PSSM (Jensen et al.,
2006) and the Raymond combined 11/25 and net charge rules (Raymond et al., 2010),
all of these approaches have been optimised for coreceptor tropism prediction in sub-
type B and show varying levels of sensitivity at predicting CXCR4-usage in subtype B
(Garrido et al., 2008; Poveda et al., 2010).
1.10 CXCR4-usage in HIV-1 subtype C
Despite HIV-1 subtype C accounting for almost 60% of worldwide HIV infections
(Requejo, 2006), little is known about the prevalence and patterns of CXCR4-usage
in this subtype. Earlier studies have suggested that a switch to CXCR4-usage was
rare or never occurred in subtype C (Abebe et al., 1999; Cecilia et al., 2000). How-
ever, an increasing number of recent studies have shown that a switch from CCR5-
to CXCR4-usage can and does occur (Cilliers et al., 2003; Pollakis et al., 2004). Cil-
liers and colleagues demonstrated that CCR5 and CXCR4 receptors are both used by
HIV-1 subtype C (Cilliers et al., 2003). Pollakis and colleagues likewise reported that
a switch from CCR5- to CXCR4-usage does occur in subtype C, and does so in a man-
ner similar to that of subtype B (Pollakis et al., 2004). A recent study by Esbjornsson
and colleagues reported a frequency of 15% CXCR4-usage in subtype C sequences
(Esbjo¨rnsson et al., 2010). In addition, a study by Connell and colleagues reported
that of the 20 South African AIDS patients they examined (19 of which had subtype C
infections), 30% of primary isolates were CXCR4-using, indicating an increase in fre-
quency of CXCR4-usage in subtype C over time (Connell et al., 2008). However, these
studies were conducted on a relatively small number of subtype C sequences while the
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geographical range of sampling was limited.
Furthermore, the genetic determinants of the switch in coreceptor use are less-well
understood than in subtype B. Conflicting reports have been published with some sug-
gesting that these determinants are the same for subtype C as subtype B (Raymond
et al., 2010), while others have presented evidence to the contrary (Jensen et al., 2006).
Jensen and colleagues developed the only subtype C specific genotyping tool with a
reported sensitivity of 75% (Jensen et al., 2006) while others evaluated the ability of
this and other algorithms trained on subtype B data at correctly predicting CXCR4-use
in subtype C sequence data (Raymond et al., 2010). They found that the most ap-
propriate approach for predicting CXCR4-usage in subtype C were C-PSSM and their
combined 11/25 and net charge rule (Raymond et al., 2010). When specificity was
considered, however, Raymond and colleagues approach was significantly better than
C-PSSM (96.4% versus 81.8%). The dataset used in this study, however, did not repre-
sent the entire spectrum of HIV-1 subtype C diversity in that it had a limited number of
phenotyped sequences (55 R5 and 15 X4 sequences) collected from only two countries
(Malawi and France).
Although maraviroc (Selzentri R ) is in use worldwide, Food and Drug Adminis-
tration (FDA) regulations have made tropism testing compulsory prior to its prescrip-
tion. In resource limited settings, phenotypic methods are often too costly and require
specialized facilities. Genotypic testing thus represents a viable alternative for use
in a clinical setting. This holds particularly true for a country such as South Africa
where the number of people receiving treatment is currently in excess of 2 million, and
genotyping represents the only real alternative. Validation and improving the accu-
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racy of the available genotypic algorithms thus becomes imperative in the fight against
HIV/AIDS. The relevance of this study is further increased by the recent approval of
maraviroc/celsentri (Selzentri R ) for use in South Africa in January 2014.
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1.11 Thesis Rationale
The overall objectives of this project were to:
1- Analyse the predictive ability of available genotypic algorithms in their pre-
diction of coreceptor tropism in HIV-1 subtype C.
A large dataset consisting of all available HIV-1subtype C envelope V3 loop sequences
with phenotypically verified coreceptor tropism were used to evaluate the performance
of currently available genotyping tools.
2- Evaluate the effect of the conflicting signal from dual-tropic viruses on geno-
typic algorithm evaluation.
CXCR4-using viruses were separated into CXCR4-exclusive and dual-tropic viruses,
and the possible conflicting signal from the dual-tropic viruses on the ability of the
genotypic approaches to correctly predict coreceptor phenotype was examined.
3- Determine prevalence and mode of CXCR4-usage in HIV-1 Subtype C.
A second larger dataset of subtype C V3 loop sequences with experimentally unde-
termined coreceptor tropism was genotypically characterized, and used to determine
the prevalence of CXCR4-usage over time as well as to characterise the emergence of
CXCR4-usage in HIV-1 subtype C.
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1.12 Thesis Outline
Chapter 1 Introduction: This chapter forms a general introduction to the Human Im-
munodeficiency Virus. It briefly describes aspects of the virus’ biology related to core-
ceptor tropism. This chapter also provides an outline of the objectives of this study, as
well as the rationale for undertaking it.
Chapter 2 Methodology: In this chapter, the various methodologies employed in
this research, as well as the rationales behind them are explained. It details the way in
which genotypic tools were evaluated as well as how the effect of potential conflicting
signal from dual-tropic viruses was determined. It also deals with the methodologies
used to determine the prevalence and mode of CXCR4-usage in HIV-1 Subtype C.
Chapter 3 Results: The results of the experiments carried out are described and
analyzed in this chapter. The way in which genotypic algorithms handle ambiguous
base pairs in sequences is presented. Genotypic algorithms are compared to deter-
mine which is most suitable for coreceptor tropism prediction in subtype C, in terms
of sensitivity, specificity as well as overall accuracy of these tools. The ability of these
algorithms to handle dual tropic viral sequences is uncovered. Finally, the prevalence
of CXCR4-usage in the subtype C viral population over time is determined.
Chapter 4 Discussion: This findings of this study are discussed in the context of
similar works done on coreceptor usage in HIV subtypes, particularly subtype C. Lim-
itations of this study are discussed here too.
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Chapter 5 Conclusion: This is the final chapter of the thesis and draws conclusions
from the analysis of the results seen in Chapter 3 and the observations made in the
preceding chapter.
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Chapter 2
Methodology
2.1 Dataset Curation: Appraising the Performance of
Coreceptor Genotyping Tools at Accurately Predict-
ing Coreceptor Usage in HIV-1 Group M Subtype
C.
To evaluate the performance of each of the available genotypic tools currently used to
predict subtype B tropism, and determine which of these performed best on subtype
C sequences, a dataset of 731 sequences with known coreceptor tropism was collated.
First, a comprehensive search of the Los Alamos National Laboratory (LANL) HIV
Sequence Database (hiv.lanl.gov) was undertaken and 604 sequences using the CCR5
coreceptor only, 53 using the CXCR4 coreceptor only and 43 dual tropic sequences
(R5X4) were retrieved. A search of published literature resulted in the addition of 31
more sequences, of which 22 were denoted as CCR5 and 9 as R5X4 sequences (Jensen
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et al., 2006; Raymond et al., 2010).
The inclusion of multiple sequences from an individual at the same time point
could bias the estimation of the accuracy of a genotypic tool. To avoid this potential
bias in results, multiple samples from the same individuals were excluded with a single
representative sequence randomly selected for each of these individuals.
Multiple sequence alignments of each of the V3 nucleotide sequences were then
produced manually using MacClade 4.08 software (Maddison and Maddison, 1992).
To ensure alignment consistency, all sequences were aligned to the LANL retrieved
HXB2 reference sequence (Korber et al., 1998). Comparing sample sequences to the
reference sequence not only allows reference to be made to specifically numbered nu-
cleotide bases relative to the reference sequence, but also facilitates identification of
inserted and deleted bases.
2.2 Handling of Ambiguous Nucleotide Bases
Several of the sequences in the dataset contained degenerate base symbols, represent-
ing multiple possible alternatives for a single base position within a codon. The pres-
ence of these ambiguous nucleotide calls in a sequence can affect the accuracy of
genotyping approaches as each of these algorithms is based on the presence or absence
of positively or negatively charged amino acids at specific locations within the genome
(Sing et al., 2007b). Geno2pheno is the only one of the tools tested that is capable of
accounting for ambiguous nucleotides in its genotypic predictions (Sing et al., 2007b).
In this instance, the sequences containing ambiguous base symbols were included with
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all other sequences in the analysis with the geno2pheno web-tool.
The exclusion of these sequences with ambiguous base positions from the analyses
with the remaining genotypic tools could artificially influence sensitivity, specificity
and accuracy calculations. Thus, if a tested genotyping approach was not designed
to account for ambiguous nucleotide positions, all possible combinations of amino
acid sequences were output for the sequences containing ambiguous positions, us-
ing a script written in Python (RK Shrestha), and each of these was submitted for
genotypic testing. The genotypic call of the translated sequences was compared. A
worst-case scenario approach similar to that of Sing et al. (Sing et al., 2007b) was em-
ployed whereby if one of these translated sequences was predicted as CXCR4-using,
the genotyping call for the original sequence was taken to be X4.
2.3 Genotypic Algorithm Evaluation
Viral sequences were separated into three distinct categories based upon their exper-
imentally verified viral phenotype: CCR5-using (R5), CXCR4-using (X4) and dual–
tropic (R5X4). Dual-tropic and CXCR4-tropic viruses were studied both separately
and together (as CXCR4-using) in order to determine the affect of the conflicting sig-
nal of dual-tropic viruses on the sensitivity of each tool.
The coreceptor tropism of every V3 sequence in each of the categories was pre-
dicted using a number of genotyping methods. These comprised the Position Spe-
cific Scoring Matrix (PSSM) tools, including PSSMX4R5 and PSSMSINSI (Jensen et al.,
2003) as well as the subtype C PSSM tool (Jensen et al., 2006); geno2pheno (Sing
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et al., 2007b) and four variants of the wetcat package, including C4.5, C4.5 with p8-
p12, PART and SVM (Pillai et al., 2003). Tropism was also predicted using the 11/25
(Fouchier et al., 1992) and 11/24/25 (Cardozo et al., 2007) charge rules. Raymond and
colleagues recently proposed a combination of the 11/25 and charge rules for predic-
tion of CXCR4-use in subtype C sequences (Raymond et al., 2010), and this method
was evaluated too.
2.3.1 Web PSSM matrices
CCR5, CXCR4 and R5X4 sequences were submitted for genotypic testing to each
of the Web PSSM tools as separate sub-datasets, using default settings. The genotypic
call for each sequence was determined based on the percentile given for each sequence,
where a percentile score of 0.96 and above were considered as CXCR4-using while
those below this value were considered as R5. When more than one optimal alignment
to the HXB2 reference sequence could be determined by the Web PSSM tools for each
of the submitted sequences, multiple output sequences along with their results were
generated. These sequences were only considered for further analysis when genotypic
predictions made by the matrix were the same for all alignment variations.
2.3.2 Geno2pheno
Sequences in each coreceptor dataset were split into groups of 50 or fewer to meet the
maximum handling capability of the geno2pheno web based tool. In selecting how
conservative the detection of CXCR4-usage should be, cut-offs of 5%, 10% and 20%
were used in this study to determine coreceptor usage with geno2pheno. For clarity
purposes, each of the geno2pheno false positive rates used is described as an individual
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approach throughout this thesis.
2.3.3 Wetcat package
Four of the five classifiers in the wetcat package were evaluated in this study. These
included C4.5, C4.5 with positions 8 and 12 only, PART and SVM. According to on-
line instructions, all V3 sequences were aligned to the 40 base pair consensus sequence
provided on the website, which was designed on training data obtained from the Los
Alamos Database. Due to the unconventional length of the consensus V3 sequence,
the fifth wetcat classifier, the Charge Rule, was not used in this study. Particular care
was taken in aligning test sequences to position 12 in the wetcat alignment, which
corresponds to position 11 according to public consensus and is known to be a ma-
jor determinant in coreceptor determination. The number of correctly and incorrectly
predicted sequences was determined for each dataset.
2.3.4 Charge rules
The 11/25 and 11/24/25 charge rules were assessed using a script written in Python (C
Meehan), and sequences were predicted as CXCR4-using or CCR5-using based on the
principles relevant to each method. Both of these rules use sequence features of the
V3 loop exclusively to predict coreceptor usage (Sander et al., 2007). For the 11/25
rule, sequences were determined to be X4-using if a positive charge was found at either
position 11 and/or 25 of the V3 loop (Fouchier et al., 1992). The positively charged
amino acids are Arginine (R), Lysine (K), and Histidine (H). Similarly, if a positive
charge was present at the 11, 24 and/or 25 positions of the V3 loop, the virus was
predicted to be CXCR4-using according to the 11/24/25 rule (Cardozo et al., 2007).
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2.3.5 Raymond method
Raymond and colleagues recently proposed a combination of the 11/25 and charge
rules for prediction of CXCR4-use in subtype C sequences (Raymond et al., 2010).
One of the following criteria is required for predicting CXCR4 coreceptor usage:
(1) a R or K at position 11 and/or a K at position 25,
(2) a R at position 25 and a net charge of greater than or equal to +5, or
(3) a net charge of greater than or equal to +6 (Raymond et al., 2010).
A script implementing these rules was written in Python (RK Shrestha) and used to
assess sequences in each of the sub-datasets. Sequences that did not satisfy any of the
criteria were classified as CCR5-using.
2.4 Determining Sensitivity and Specificity of Genotypic
Algorithms
Both the ability of an algorithm to correctly predict CXCR4-usage and its ability to cor-
rectly predict CCR5-usage in an HIV-infected individual are important in determining
the best genotypic approach. Sensitivity corresponds to the ability of the approach to
correctly predict CXCR4-use, while specificity corresponds to the ability to correctly
predict CCR5-usage. The perfect approach would therefore have 100% sensitivity and
100% specificity and would be able to correctly distinguish between R5 and X4-using
viruses.
To calculate each of these statistical values, the number of True Positive (TP), False
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Positive (FP), True Negative (TN) and False Negative (FN) sequences were recorded,
where:
• True positive refers to the number of CXCR4-using sequences correctly pre-
dicted as CXCR4-using.
• False positive refers to the number of CCR5-using sequences incorrectly pre-
dicted as CXCR4-using.
• True negative refers to the number of CCR5-using sequences correctly pre-
dicted as CCR5-using sequences.
• False negative refers to the number of CXCR4-using sequences incorrectly pre-
dicted as CCR5-using sequences.
The sensitivity of each approach for CXCR4 prediction was calculated as the num-
ber of predicted X4 viruses in the CXCR4-using dataset divided by the total number
of sequences in the CXCR4-using dataset. This can be expressed as:
TP
TP + FN
The specificity of each approach for CXCR4 prediction was calculated as the num-
ber of predicted R5 viruses in the CCR5-using dataset divided by the total number of
sequences in the CCR5-using dataset. This can be expressed as:
TN
TN + FP
The same statistical approach was used to calculate the sensitivity and specificity
of each genotyping method on the CXCR4-exclusive and dual-tropic datasets.
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2.5 Determining Accuracy of Genotypic Algorithms
Although sensitivity and specificity are both useful measures in determining the pre-
dictive ability of an algorithm, neither is a true measure on its own of how good an
algorithm is at predicting tropism, and a measure taking both values into account is
required. Therefore, an overall accuracy score for each of the approaches used was
calculated using:
TP + TN
TP + TN + FP + FN
where, TP, TN, FP and FN are defined as above. For the CXCR4-exclusive dataset the
TP and FN values were calculated only for sequences phenotypically determined to
exclusively use CXCR4. For each calculation, the TP and FN values were normalised
relative to the TN and FP values to account for the disproportionate number of se-
quences representing the positive (CXCR4-using or CXCR4-exclusive) and negative
(CCR5) datasets (see Appendix 1 for the uncorrected values used to calculate accu-
racy). This was done by multiplying each of the TP and FN values by the difference in
ratio between the total number of CCR5 (TN + FP) sequences and the total number of
CXCR4-using sequences (TP + FN).
2.6 Determining Effect of Dual Tropic Viruses on Pre-
diction of CXCR4-usage
Dual tropic viruses can enter host cells using either CCR5 or CXCR4 chemokine re-
ceptors and, in some instances, display preferential use for one of these. This may
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result in mis-prediction of some X4-capable viruses as R5 using. In order to deter-
mine the affect of the conflicting signal of dual-tropic viruses on sensitivity estimates,
dual-tropic and CXCR4-tropic viruses were studied both separately and together (as
CXCR4-using). For this purpose, viral sequences were separated into three distinct
categories ( R5, X4 and R5X4) based upon their experimentally verified viral pheno-
type and tested as separate sub-datasets on each of the genotypic tools.
2.7 Dataset Curation: Prevalence of CXCR4-usage in
Subtype C
Once the most accurate genotyping tool was established for the prediction of corecep-
tor tropism in subtype C (as described above), this tool was then used to determine the
genotype of all the available subtype C V3 loop sequences. To do this, a comprehen-
sive search of the LANL database and literature for every available HIV-1 subtype C
V3 loop sequences was conducted. This second, larger dataset, comprising of a total of
17,353 individual sequences, was largely composed of sequences with unknown phe-
notypes. Epidemiological and demographic data including subtype, phenotype (where
available), sampling year, country of origin, as well as sequence accession number
and name was recorded for each sequence. Multiple sequences for the same patient,
including clonal sequences from longitudinal studies, were excluded, retaining one,
randomly chosen, representative sequence for each of these individuals.
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2.8 Multiple Sequence Alignment Using RAMICS
Because of the large number of sequences contained in this dataset, an alternative
to the McClade software previously used to align multiple sequences for genotypic
testing was used. While MacClade requires the alignment of multiple sequence to
be undertaken manually, alignment in RAMICS (Rapid Amplicon Mapping in Codon
Space) is automated. Furthermore, McClade was only able to handle a maximum of
500 sequences at a time, while RAMICS was able to simultaneously align sequences
from all individuals to the LANL sourced HXB2 reference sequence. RAMICS is
a novel tool employing hidden Markov models to align multiple sequences in codon
space. In doing so, it is able to take into consideration both the nucleotide and the
amino acid for every position in the reference sequence. It also takes into account and
compares the likelihood of insertions, deletions and mutations at each position of the
reference sequence (Wright et al., currently under review in Nucleic Acids Research).
2.9 Coreceptor Tropism Prediction
Coreceptor tropism predictions were done using geno2pheno as it was previously seen
to be the best approach for subtype C coreceptor genotyping (see results). Due to the
large number of sequences it contained, the dataset was run in batch mode through
geno2pheno by Alexander Thielen. On return of the predicted dataset, the coreceptor
tropism of each sequence was then determined based on the significance level previ-
ously established to be the most suitable cutoff.
34
 
 
 
 
2. METHODOLOGY
2.10 Exploring Prevalence and Patterns of CXCR4-usage
in Subtype C
To investigate CXCR4 coreceptor usage in subtype C, we explored the genotyping
results from the large dataset containing all available subtype C V3 loop sequences.
In order to determine if the epidemic was evolving over time, a direct comparison was
performed and the dataset was split into an early (samples between 1984 and 1997) and
a late group (samples between 1998 and 2010) (Connell et al., 2008). CXCR4-usage
was plotted for each year to determine the prevalence of CXCR4-usage over time and
to characterise the emergence of CXCR4-usage. To determine CXCR4-usage patterns
of subtype C in earlier sampled sequences, the first identification of CXCR4-usage in
HIV-1 subtype C sequence database records was dated.
The geographical occurrence of subtype C and, more specifically CXCR4-using
sequences, were also determined by comparing the number of subtype C and CXCR4-
using sequences for each country. By comparing the dates for the emergence of
CXCR4-usage in each country, the spread of CXCR4-usage within countries could
be compared and the CXCR4-usage patterns in subtype C could be established. In this
way, potential expansion of CXCR4-usage in subtype C could be identified. The earli-
est identification of CXCR4-usage was further analysed for countries with the highest
numbers of subtype C sequences. Furthermore, by analyzing the geographical data of
all available subtype C V3 loop sequences over the years, we attempted to explore any
geographic disparities in the emergence of CXCR4-usage in subtype C over the entire
period of time for which records are available.
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2.11 Maximum Likelihood Phylogeny Estimation
To facilitate downstream analysis, each sequence descriptor in the dataset was ap-
pended with its coreceptor prediction. Phylogenetic relationships of all available sub-
type C V3 sequences, with genotypically determined coreceptor tropism, were inferred
by the maximum likelihood approach implemented in RAxML v7.0.4 MPI algorithm
(Stamatakis, 2006). The GTRGamma model of nucleotide substitution was employed
with 100 replicate bootstrap support. To root the tree, the HXB2 reference sequence
was used as the outgroup. FigTree v1.3.0. (http://tree.bio.ed.ac.uk/software/figtree/)
was used to explore the spatial clustering patterns within the resulting phylogeny.
Clustering was explored on the basis of tropism, country of origin and sampling year.
Supports within the phylogeny were explored and any relationships supported with a
bootstrap value greater than 70 were taken as significant.
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Chapter 3
Results
3.1 Dataset Compilation: Appraising the Performance
of Coreceptor Genotyping Tools at Accurately Pre-
dicting Coreceptor Usage in HIV-1 Group M Sub-
type C.
A total of 731 HIV-1 group M subtype C V3 sequences with experimentally verified
coreceptor tropism were initially sourced from the Los Alamos National Laboratory
(LANL) HIV Sequence Database (hiv.lanl.gov) and published literature. Of these, 604
sequences using the CCR5 coreceptor only, 53 using the CXCR4 coreceptor only and
43 dual tropic sequences (R5X4) were retrieved from LANL. The remaining 31 se-
quences were sourced from published literature, of which 22 were denoted as CCR5
and 9 as R5X4 sequences (Jensen et al., 2006; Raymond et al., 2010).
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Table 3.1: Number of CCR5, CXCR4 and dual tropic sequences obtained from each
source.
Source CCR5-using CXCR4-using Dual tropic
LANL 327 25 22
Raymond et al. 3 0 3
Coetzer et al. 19 0 6
Total: 349 25 31
Number of phenotypically determined HIV-1 subtype C sequences obtained from each
source.
Furthermore, multiple sequences from individuals were removed, and only one ran-
domly selected representative sequence for each individual was retained, reducing the
total number of sequences to 405 (Table 3.1). The final analysis dataset contained V3
loop sequences from 349 CCR5-using and 56 CXCR4-using viruses. Sequences from
CXCR4-using viruses were further separated into R5X4 (dual-tropic) and CXCR4-
exclusive viruses with 31 and 25 sequences, respectively, comprising these datasets.
3.2 Handling of Ambiguous Nucleotide Bases
The coreceptor usage of every sequence in each of the datasets was predicted using
all of the genotyping approaches. Twenty-three of the sequences tested contained at
least one ambiguous nucleotide position, and none contained more than four ambigu-
ous base pairs. Of these 23 sequences, 18 were CCR5, one CXCR4 and four dual
tropic. Geno2pheno is the only one of the tools tested that is capable of accounting for
ambiguous positions in its genotypic predictions (Sing et al., 2007b). To assess all of
the other approaches, nucleotide sequences were translated into all the possible combi-
nations of amino acid sequences and if one or more of these translated sequences was
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predicted as CXCR4-using, the genotyping call for the original sequence was taken
as X4. However, for none of the sequences was this approach necessary, as the re-
solved sequences for each of the ambiguous-containing sequences were predicted to
have the same coreceptor usage for each of the methods. Additional sequences gener-
ated through the translational process were excluded from the study so as to prevent
inflation of sequence numbers. For each of the 23 sequences, all possible translations
of the sequence had the same coreceptor tropism prediction for each method. Thus, in
this data, ambiguous positions did not affect the genotypic predictions.
3.3 Sensitivity and Specificity of Genotypic Algorithms
The sensitivity of each of the tested approaches at predicting X4 viruses in the CXCR4-
using dataset (dual tropic and CXCR4-exclusive combined) varied widely from 40-
97% (Figure 3.1 and Table 3.2). The method by Raymond and colleagues had the
highest sensitivity at 97% while geno2pheno (FPR20) and C-PSSM both exhibited high
sensitivities of greater than 90%. Two variants of the wetcat package, C4.5 and C4.5
with p8-p12, performed most poorly with sensitivities of 40% each.
The specificity of each approach was also calculated, where specificity corresponded
to the number of CCR5-tropic viruses correctly predicted as R5 divided by the total
number of CCR5-using viral sequences evaluated. All approaches performed well
with three having 100% specificity, eight having specificity greater than 90% and
geno2pheno FPR20 and the Raymond method exhibiting lower specificity of 86% and
76% respectively (Figure 3.1 and Table 3.2).
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Table 3.2: Performance of genotyping approaches at predicting CXCR4-usage in viral
sequences from individuals infected with HIV-1 group M subtype C.
Method CXCR4-using sensitivity (%) Specificity
PSSMsinsi 76 100
PSSMX4R5 75 97
C-PSSM 90 92
Geno2Pheno FPR5 89 99
Geno2Pheno FPR10 89 94
Geno2Pheno FPR20 91 86
WetCat C4.5 40 99
WetCat C4.5pos.8&12 40 100
WetCat PART 53 100
WetCat SVM 63 99
11/24/25 68 97
11/25 60 99
Raymond Approach 97 76
Sensitivity corresponds to the ability of the approach to predict CXCR4-use, while
specificity corresponds to the ability to correctly predict CCR5-use.
3.4 Genotypic Algorithm Evaluation
Sensitivity and specificity for the Raymond method were estimated at 97% and 76%
respectively for their approach in this study. Compared to the other approaches tested,
however, Raymonds method is not the optimal approach. While it does show the high-
est sensitivity, it also has the lowest specificity of all the approaches tested (Table 3.2).
For the other approaches it is found that specificity increases by as much as 24% for
three of the approaches relative to the Raymond study, and 23% for a further four ap-
proaches.
The sensitivities of the three geno2pheno approaches tested here showed little dif-
ference, with geno2pheno FPR5 and FPR10 both having sensitivities of 89% and dif-
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fering by only 2% more than FPR20. However, the specificities of these approaches
showed a greater difference, with specificities differing by up to 13% between ap-
proaches.
Web C-PSSM was the only one of the genotypic algorithms tested that was de-
signed based on a subtype C sequence training dataset. Although not the method with
the highest overall sensitivity, the C-PSSM approach out-performed both other PSSM
approaches at correctly predicting CCR5 usage. A difference of 15% and 14% in speci-
ficity was recorded between it and PSSMX4R5 and PSSMsinsi respectively in this study.
Overall, compared to the other approaches tested, the wetcat package of tools per-
formed most poorly in predicting CXCR4-usage in subtype C. There was no difference
in the way two variants of the wetcat package, C4.5 and C4.5 with p8-p12 performed,
with each having the lowest ability to correctly predict CXCR4-usage.
3.5 Accuracy of Genotypic Algorithms
While some methods are extremely sensitive at correctly predicting CXCR4-use, the
optimum approach for clinical implementation also needs to be highly specific in cor-
rectly identifying viruses that do not use the CXCR4 receptor. Thus, an accuracy score
was calculated for each of the approaches tested that takes into account an approaches
sensitivity and specificity (Table 3.3). For the CXCR4-using dataset, it was found that
three of the 13 approaches tested have an accuracy of 90% or greater at predicting
coreceptor usage in HIV-1 group M subtype C viral sequences with geno2pheno FPR5
being the most accurate of all approaches tested with an accuracy of 94% (89% sen-
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Table 3.3: Accuracy of genotyping approaches at correctly predicting coreceptor
tropism.
Method CXCR4-using CXCR4-exclusive R5X4
accuracy accuracy accuracy
PSSMsinsi 88 88 88
PSSMX4R5 86 87 86
C-PSSM 91 90 91
Geno2Pheno FPR5 94 93 94
Geno2Pheno FPR10 92 91 92
Geno2Pheno FPR20 88 87 90
WetCat C4.5 70 70 70
WetCat C4.5pos.8&12 70 70 70
WetCat PART 77 76 79
WetCat SVM 81 82 81
11/24/25 81 81 82
11/25 79 76 82
Raymond Approach 86 88 85
Accuracy scores are presented for a combined dataset containing CXCR4-using viruses
(both CXCR4-exclusive and dual-tropic viruses) as well as separately for the CXCR4-
exclusive and dual-tropic viral sequences.
sitivity and 99% specificity, Table 3.3). Two variants of the wetcat package, C4.5 and
C4.5 with p8-p12, both perform poorest with accuracy scores of 70% (Table 3.3).
3.6 Effect of Dual Tropic Viruses on Prediction of CXCR4-
usage
The CXCR4-using viruses were separated into CXCR4-exclusive and dual-tropic viral
sequences and the accuracy of each of the approaches at correctly predicting coreceptor
tropism was calculated (Table 3.3). When dual-tropic sequences are excluded, the
accuracy of three of the approaches increases minimally, with four methods showing
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no change in accuracy and six showing a slight decrease of 1% in accuracy (Table
3.3). Similarly, when the dual-tropic viruses were studied separately there was minimal
effect on the accuracy of each of the approaches when compared to CXCR4-exclusive
viruses (Figure 3.2). There was significant variability in the ability of the approaches
to accurately predict CXCR4-usage in dual-tropic viruses, ranging from 40% (wetcat
C4.5 with p8-p12) to 94% (geno2pheno FPR20) of sequences from dual-tropic viruses
predicted as CXCR4-using (Figure 3.2). It appears that, in subtype C at least, the
ability of approaches to predict CXCR4- usage in dual tropic viruses directly correlates
with their ability to predict CXCR4-usage in CXCR4-exclusive viruses.
3.7 Dataset Compilation: Prevalence andMode of CXCR4-
usage in Subtype C
A total of 17,353 HIV-1 group M subtype C V3 sequences were initially retrieved from
the LANL sequence database and published literature. This dataset was largely com-
posed of viral sequences with experimentally undetermined phenotypes. The exclusion
of multiple sequences for the same patient reduced the dataset to a final total of 12,121
sequences, which was used to determine the prevalence of CXCR4-usage in subtype
C. This was done using geno2pheno (FPR5), which was previously determined to be
the most accurate approach for HIV-1 subtype C tropism determination.
3.8 Multiple Sequence Alignment Using RAMICS
The RAMICS tool for multiple sequence alignment was found to be robust, accurate
and generated biologically relevant multiple sequence alignments rapidly. RAMICS
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was able to handle a considerably large number of sequences simultaneously - in this
instance, a total number of 12,121 sequences were aligned to the HXB2 reference
sequence in 35.2 seconds. This approach to sequence alignment ensured consistency
in handing insertions, deletions and mutations throughout the alignments and was able
to account for variances in length.
3.9 CXCR4-usage Patterns in HIV-1 Subtype C Sequences
From its first emergence in database records in 1988, the presence of sampled subtype
C CXCR4-using sequences is not seen consistently over the years, up until a decade
later (Figure 3.3). From 1998 onwards the presence of X4 sequences appears to sta-
bilize between 4 – 9% per year (Figure 3.3). The largest number of CXCR4-using
sequences were identified in sequences generated from samples collected in 1997, at
16% of the total number of sequences for that year (Figure 3.3). These 31 sequences
were all from India (Figure 3.4e). In total, CXCR4-using sequences comprised less
than 5% of the entire subtype C dataset, while CCR5 sequences make up a signifi-
cantly larger proportion of the 12,121 subtype C sequences in this dataset at over 95%.
Sequenced subtype C viral sequences first appear in the database records in 1984
(Figure 3.5). For this year, eight sequences were recorded - all of which were predicted
as CCR5-using. A notable increase in the number of recorded subtype C sequences is
seen in 1988 with a total of 121 sequences recorded for this year - 2 of which were
CXCR4-using from Ethiopia. This figure peaks in 2005, when the largest number of
recorded subtype C sequences was 1,397. Of these, 96% were CCR5-using sequences
while 4% were CXCR4-using sequences.
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The earliest appearance of CXCR4-using sequences in the LANL database dates to
1988 when three sequences were recorded - two of which were from Ethiopia, while
one came from Malawi (Figure 3.4). The earliest observations of sequenced CXCR4-
using sequences in the database records do not appear to be consistent for all countries,
with CXCR4-usage first appearing in South African records in 1990, Tanzania in 1995,
while India and Zambia subtype C CXCR4-using sequences first appear a decade later
in the year 2000 and for Zimbabwe in 2001.
3.10 Prevalence of CXCR4-usage in HIV-1 Subtype C
sequences
Of the 77 countries from which the 12,121 sequences derive, 60 have fewer than 100
subtype C sequences each in the LANL database, while nine countries have between
100 and 200 subtype C sequences each. To better understand the patterns of CXCR4-
usage, larger groups of subtype C sequences were studied in more detail. Thus, coun-
tries with more than 200 representative subtype C sequences were selected for further
analysis, including CXCR4-usage over time. Of the eight countries that have above
200 subtype C sequences (Table 3.4), excluding India, which has a total of 1,201 sub-
type C sequences, all are African countries, and include: Botswana, Ethiopia, Tanza-
nia, Zimbabwe, South Africa, Malawi and Zambia. The largest number of subtype C
sequences recorded came from Zambia, with a total of 2,804 unique sequences (See
Appendix B).
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Table 3.4: Number of predicted R5 and X4 sequences for countries with more than
200 subtype C sequences each.
Country of Total number Predicted Predicted
origin of sequences CCR5-using CXCR4-using
Botswana 225 221 4
Ethiopia 467 426 41
Tanzania 479 464 15
Zimbabwe 612 564 48
India 1201 1191 10
South Africa 2265 2151 114
Malawi 2462 2371 91
Zambia 2804 2698 106
In this study, the proportion of CXCR4-using sequences is not seen to be consistent
for each country. While Malawi and Zambia were the countries with highest number
of subtype C sequences recorded (each with over 2,000 subtype C sequences seen) (Ta-
ble 3.4), the proportion of CXCR4-using sequences for these countries was relatively
low at around 4% of the total subtype C viral population (Figure 3.6). In contrast to
this, the highest proportion of CXCR4-using viral sequences were seen in Ethiopia and
Zimbabwe, with 9% and 8% respectively (Figure 3.6) despite each of these countries
showing fewer than 500 subtype C sequences each in the LANL database. Although
it was one of the countries with the greatest number of subtype C sequences listed, at
1%, India had the lowest proportion of observed CXCR4-using sequences recorded.
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Figure 3.6: Proportion of CXCR4-using sequences from countries with more than 200
subtype C sequences each.
3.11 Maximum Likelihood Phylogeny Estimation
The GTRGamma substitution model was used since it was found by to be the most
appropriate substitution model according to ModelTest (Posada and Crandall, 1998).
Phylogenetic analysis based on 12,121 subtype C env V3 loop sequences showed that
CXCR4-using sequences were spread throughout the phylogeny. This observation was
indicative of the convergent evolution in the development of CXCR4-usage in HIV-1
Group M subtype C (Figure 3.7). No significant clustering patterns of CXCR4-using
sequences are found, indicating that CXCR4 receptor usage has arisen independently
in different subtype C populations, as opposed to being established by founder effect.
CXCR4-using sequences are spread throughout the tree, suggesting that X4 usage is
not being transmitted, but rather evolving within individuals.
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0.2
Figure 3.7: Distribution of CCR5 (green) and CXCR4-using (red) sequences with
bootstrap values greater than or equal to 70 highlighted. The tree was rooted with
the HXB2 reference sequence (shown in black). Horizontal branch lengths are drawn
to scale with the bar at the bottom indicating nucleotide substitutions per site.
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The phylogeny was fairly well supported, with bootstrap estimates of 70% and
above occurring throughout the tree (Figure 3.7). The greatest support for the phy-
logeny at bootstrap confidence values of 70% and above was found at the terminal
nodes, with few basal branches providing support at this level. However, the backbone
of the lineage was not well supported, with little support found deeper in the phy-
logeny. This is further supported by the many short branch lengths seen deeper in the
tree. Of note is a long branch midway in the phylogeny representing a group of highly
divergent sequences.
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Chapter 4
Discussion
This is the first study to determine the effect of sequences from dual tropic viruses
on the sensitivity of genotyping methods. Furthermore, it is the first comprehensive
study using all available subtype C sequences with experimentally verified coreceptor
tropism to evaluate the performance of various genotyping tools at accurately predict-
ing CXCR4-usage in HIV-1 subtype C. It is also the first study to undertake a large-
scale analysis of the emergence and prevalence of CXCR4 coreceptor usage in HIV-1
group M subtype C, using a geographically diverse dataset.
4.1 Ability to Account for Ambiguous Nucleotide Posi-
tions
The presence of ambiguous nucleotide calls, particularly within the codons encod-
ing for amino acid positions 11, 24 and 25, can substantially reduce the ability of
approaches to correctly predict coreceptor usage (Sing et al., 2007b). The clinical ap-
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plication of genotypic tropism testing must often account for viral sequences with such
ambiguous nucleotide calls. Previous studies have shown that the accuracy of geno-
typic tropism prediction methods is lower on clinically derived data than on clonal data
(Sing et al., 2007b; Bozek et al., 2013). In a recent study, Bozek and colleagues exam-
ined the effect of amino-acid ambiguities on the prediction accuracy of several clinical
models for tropism prediction. The results of three datasets were compared: one with-
out any ambiguous sequences, another with ambiguous sequences and the third dataset
having all ambiguous position replaced by gaps. It was found that combined infor-
mation from both types of positions is important for tropism prediction (Bozek et al.,
2013). Geno2pheno is the only one of the tools tested that is capable of accounting for
ambiguous base positions in its genotypic predictions, while none of the other methods
were designed to handle ambiguous base positions. Thus, in our study it was found
that the ability to account for ambiguous nucleotide positions in geno2pheno gives it a
distinct advantage over all of the other approaches tested.
4.2 Effect of Dual Tropic Viruses on Prediction of CXCR4-
usage
Dual-tropic viruses are a unique class of viruses in that they can enter host cells using
either CCR5 or CXCR4 chemokine receptors. However, some dual-tropic viruses can
exhibit preferential use of one of these (Berger et al., 1998; Huang et al., 2007, 2009).
From a clinical perspective, it is imperative that genotyping approaches correctly iden-
tify the CXCR4-using capabilities of dual-tropic viruses. Genotyping algorithms have
been shown to vary widely in their predictive ability of CXCR4-usage in subtype B
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dual-tropic viruses (Mefford et al., 2008). In general, approaches were observed to
underestimate the frequency of CXCR4-usage in dual tropic viruses (Mefford et al.,
2008). Thus, the effect of dual-tropic viruses on the accuracy of each of the tested
genotyping approaches was assessed.
In this study it appears that, in subtype C at least, the ability of approaches to
predict CXCR4-usage in dual tropic viruses directly correlates with their ability to
predict CXCR4-usage in CXCR4-exclusive viruses. Such an observation does not
appear to hold true in subtype B, however, where some methods with high sensitivity
for prediction of CXCR4-using viruses in subtype B (Garrido et al., 2008) show low
accuracy for the prediction of CXCR4-usage in subtype B dual-tropic viral sequences
(Mefford et al., 2008). This is most likely due to a limited number of CXCR4-using
sequences in the training datasets. Geno2pheno, however, does show high accuracy for
the prediction of CXCR4-usage in subtype B dual-tropic viruses (Mefford et al., 2008).
This is probably due to the inclusion of a high number of CXCR4-using sequences in
the training dataset.
4.3 Genotypic Algorithm Evaluation
In selecting how conservative the detection of CXCR4-usage should be, German Treat-
ment Guidelines were chosen as a significance level for the geno2pheno tool in this
study, as the method most suitable for triplicate sampling (Deutsche-AIDS-Gesellschaft,
2012). The German Treatment Guidelines describe three case scenarios for the pre-
scription of CCR5 antagonists based on various false positive rates (FPR), where the
FPR is the probability of classifying an R5 virus as X4. The higher the FPR, the more
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specific the algorithm is at detecting CCR5 usage.
Taking into account the latest findings in published literature as well as from scien-
tific conferences, the German Guidelines prescribe the following treatment procedure:
for patients with several treatment options, the use of CCR5 antagonist is only recom-
mended if CXCR4-using viruses are detected at a FPR above 15%. For patients with
limited treatment options, the administration of a CCR5 antagonist may also be con-
sidered at a FPR between 5% and 15%. If the FPR is however less than 5%, the risk
of a false negative prediction is very high – in about one third of the predictions using
a FPR of 5%, CXCR4-using viruses are not detected. In these cases, CCR5 antagonist
therapy is generally not recommended. Thus, cut-offs of 5%, 10% and 20% were used
in this study to determine coreceptor usage with geno2pheno. For HIV-1 subtype C it
was found that a FPR of 5% was most accurate.
While predicting CXCR4-usage with high sensitivity is important, the ability to
correctly identify R5 variants as CCR5-using is equally as important in reducing the
amount of false positives that would result in incorrect clinical interpretations. Thus,
the specificity (proportion of CCR5-tropic viruses correctly predicted as R5) of each
approach was also calculated. All the approaches tested had high sensitivities, and per-
formed well in their ability to predict CCR5 usage. These high specificity values are
consistent with previous observations in both HIV-1 subtype B and non-B subtypes that
all approaches, in general, are better at correctly predicting CCR5-usage than CXCR4-
usage (Poveda et al., 2009; Jensen et al., 2006; Raymond et al., 2010; Garrido et al.,
2008; Seclen et al., 2010).
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Raymond and colleagues had previously evaluated nine of the 13 genotyping ap-
proaches studied here using a smaller, geographically limited subtype C dataset com-
prising 55 CCR5 and 15 CXCR4 viral sequences sampled from Malawi and France
(Raymond et al., 2010). They reported that the optimal approach for subtype C geno-
typing was a combination of the 11/ 25 and net charge rules (Raymond approach) with
sensitivity and specificity for CXCR4-usage prediction in subtype C of 93.3% and
96.4% respectively. However, when compared to the other approaches tested using a
larger and more geographically diverse dataset, Raymonds method is not the optimal
approach. While it does show the highest sensitivity, it also has the lowest specificity
of all the approaches tested. The weaker performance on our comprehensive subtype
C dataset of the combined 11/25 and net charge rule proposed by Raymond and col-
leagues is most likely an artifact of the limited sample size/diversity in their dataset
that is not present in the larger dataset studied here.
Web C-PSSM was the only one of the genotypic algorithms tested that was de-
signed based on a subtype C sequence training dataset. In describing C-PSSM, Jensen
and colleagues used a dataset consisting of 228 CCR5 sequences and 51 CXCR4 se-
quences (from 200 and 20 subjects respectively) (Jensen et al., 2006) and reported a
sensitivity of 75%, substantially less than the 90% sensitivity reported here, with com-
parable specificities of 94% and 92%.
Similarly, Garrido and colleagues evaluated the performance of eight of the sub-
type B designed approaches studied here on their ability to predict HIV-1 tropism in
non-B subtypes (Garrido et al., 2008). When compared to our results, they found that
geno2pheno performed considerably poorer on non-B subtypes, with a sensitivity of
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61% and a specificity of 73%. However, their study was composed (in part) of a rel-
atively small number of subtype C sequences, forming only 8.7% of the total non-B
subtype dataset.
In our study, two variants of the wetcat package, C4.5 and C4.5 with p8-p12, had
the lowest sensitivities of all approaches evaluated, and higher specificity values. These
findings are consistent with previous observations on both subtype B and non-B sub-
type viral sequences (Raymond et al., 2010; Garrido et al., 2008; Seclen et al., 2010).
While some methods are extremely sensitive at correctly predicting CXCR4-use,
the optimum approach for clinical implementation also needs to be highly specific in
correctly identifying viruses that do not use CXCR4, as neither is a true measure on
its own of how good an algorithm is at predicting tropism. Thus a measure taking
both values into account is required, and an accuracy score was calculated for each of
the approaches tested that takes into account an approach’s sensitivity and specificity.
Based on this method, an approach with a very high sensitivity and low specificity
scored poorly in accuracy while a fairly high sensitivity and specificity scored better in
accuracy. Thus, by taking both sensitivity and specificity into account, accuracy is the
best way to summarise the complete performance of a method.
4.4 Multiple Sequence Alignment Using RAMICS
The second dataset collated for this study consisted of 12,121 unique sequences, rep-
resenting all available subtype C V3 loop sequences. Because this many sequences
could not be accurately aligned manually, an automated approach was used to generate
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multiple sequence alignments. RAMICS was selected in favour of other widely-used
multiple sequence alignment methods, including Muscle, for its ability to generate ac-
curate, biologically relevant sequence alignments.
RAMICS is able to take into account both the nucleotide and the amino acid for
every position in the reference sequence, and compares the likelihood of insertions,
deletions and mutations at each position of the reference sequence. In so doing, it
was able to correctly account for the two amino acid insertion in the HXB2 reference
sequence in its global alignments. This feature of RAMICS was recently highlighted
in a study by Wright and colleagues, who compared the multiple sequence alignment
capabilities of RAMICS with Muscle (Wright et al., currently under review in Nucleic
Acids Research). In their study, RAMICS was able to generate significantly more
accurate alignments of HIV-1 subtype C V3 loop sequences when compared to Muscle
(Figure 4.1).
4.5 Prevalence and Patterns of CXCR4-usage in HIV-1
Subtype C
HIV-1 Subtype C accounts for over 50% of global infections and over 95% of infec-
tions in southern African countries (Hemelaar et al., 2011). Despite this, little is known
about the characteristics of this subtype, particularly those relating to its coreceptor us-
age patterns and prevalence. In this study, we assembled the largest dataset of subtype
C sequences to help elucidate the prevalence and patterns of CXCR4-usage in HIV-1
Subtype C.
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A
B
Figure 4.1: Global alignments of HIV-1 group M subtype C V3 loop sequences with
the subtype B HXB2 reference sequence generated using (A) Muscle and (B) RAM-
ICS. The codon-based alignment of RAMICS correctly discovers the relevant reading
frame for each sequence read. Further, the RAMICS alignment accurately identifies,
and accounts for in the alignment, the well-documented two amino acid insertion in
the HXB2 reference sequence.
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In the LANL database records, early reports of subtype C sequences were low with
initial reports of fewer than 10 sequences per year. From the late 1980’s onwards,
this figure began steadily increasing, with thousands of sampled subtype C sequences
reported in the following years. This surge in reported subtype C sequences could
possibly be attributed to the high infectivity of HIV-1 subtype C, leading to a greater
number of observed infections. It may also be indicative of an increased interest in
subtype C research, leading to a a greater number of sequences being sampled, espe-
cially in regions in Africa where HIV research centers are well established.
HIV-1 subtype Cwas first identified in North East Africa in the early 1980’s (Salmi-
nen et al., 1996; McCormack et al., 2002) and in this study we found that sequences
were first recorded in HIV database records from as early as 1984. HIV-1 subtype
C sequences are spread globally, with database records appearing for 77 countries.
While the majority of countries have relatively few representative subtype C sequences
recorded, some countries have a disproportionately higher number. On closer inspec-
tion, the countries with the highest number of subtype C sequences are all developing
countries, with most of these countries being in eastern and southern Africa regions.
This pattern is a reflection of the global subtype C pandemic, which sees the highest
number of HIV infections occurring in eastern and southern Africa as well as in India
(Neogi et al., 2010). In this study too, we see that India is one of the highest contribut-
ing countries to the global records of subtype C sequences.
Conflicting reports on coreceptor usage in HIV-1 subtype C have been published.
Earlier studies reported a ’remarkably’ low frequency of CXCR4-using sequences,
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with CCR5-using sequences dominating throughout infection, suggesting that a switch
to CXCR4-usage was rare or never occured in subtype C (Abebe et al., 1999). How-
ever, an increasing number of more recent studies have shown that a switch from CCR5
to CXCR4-usage can occur, and does so in a manner similar to subtype B (Cilliers
et al., 2003; Pollakis et al., 2004).
Using a substantially larger dataset with 12,121 subtype C sequences spanning 26
years, we show that a switch to CXCR4-usage is seen in subtype C for well over 20
years. This finding indicates that although seldom reported, a switch to CXCR4-usage
has consistently taken place in subtype C over time, suggesting that CXCR4-usage has
not evolved recently in this subtype. The lack of reported subtype C CXCR4-usage
in earlier studies may be as a result of sampling artifact or inadequate techniques to
determine coreceptor tropism rather than to a biological difference in this subtype.
Furthermore, it has been suggested that between 30-50% of subtype C infected in-
dividuals exhibit a change to CXCR4-usage during disease progression (Connell et al.,
2008; Kassaye et al., 2009; Michler et al., 2008; Cilliers et al., 2003; Papathanasopou-
los et al., 2002; Johnston et al., 2003). Esbjornsson and colleagues reported a frequency
of 15% CXCR4-usage in subtype C sequences (Esbjo¨rnsson et al., 2010), while a study
by Connell and colleagues reported that of the 20 South African AIDS patients they ex-
amined (19 of which had subtype C infections), 30% of primary isolates were CXCR4-
using. These higher figures, as compared to previous studies, have been suggested to
indicate an increase in frequency of CXCR4-usage in subtype C over time (Connell
et al., 2008).
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In our study, CXCR4-using sequences, at less than 5%, form a relatively small pro-
portion of the total number of sequences in the dataset of globally-derived sequences.
Although this figure is much lower than previous reports, the earlier reports were typi-
cally based on a small sample size, with sequences derived from a single study group
or country. The figure we report is likely a more accurate estimate of the frequency of
CXCR4-usage in subtype C as it is calculated as a proportion of a larger, more inclu-
sive dataset, representing sequences from 77 countries over a period of 26 years.
The high frequency of CXCR4-usage reported in some studies has also been at-
tributed to ART (anti-retroviral therapy) exposure. Pramanik Sollerkvist and colleau-
gues found that the frequency of CXCR4 use in subtype C patients failing ART’s was
higher compared to treatment naive patients (Pramanik Sollerkvist et al., 2013). Duri
and colleagues report that CCR5 usage dominated in the 28 treatment naive mother-
infant groups in their study, and that a switch to CXCR4-usage rarely happened in this
patient group (Duri et al., 2011). It has been suggested that ARTs create a suitable
environment for a switch to CXCR4-usage to take place, complicating the administra-
tion of CCR5 inhibitors to treatment-experienced patients (Pramanik Sollerkvist et al.,
2013).
4.6 Study Limitations
Despite the significance of these findings, it is important to note the limitations of this
study. One major caveat is that sequences in this study do not represent the entire
spectrum of globally circulating subtype C sequences, and are not a true reflection of
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the subtype C epidemic. Rather, they indicate the frequency of sequences observed in
database records and are not an accurate measure of the actual prevalence of subtype
C in a specific country. Because the sequence data wasn’t sampled/sequenced for this
study, we can only infer from observations in the data, however we cannot definitely
say the observations are true. Thus, we can’t draw specific conclusions about preva-
lence of coreceptor usage in these countries.
Another known caveat is the inability to account for differences between pheno-
typic assays used to determine tropism, particularly the differences between older as-
says with a generally lower sensitivity for minor variants and the newer more sensitive
assays. Furthermore, data on disease stage or therapy stage was not available for every
sequence, while it is know that samples obtained during early or late infections would
have a significant impact on the prevalence of a specific tropism.
The use of bulk or Sanger sequencing for tropism prediction may be considered as
a further confounder in this study. Here, a consensus is taken of the viral population
in an infected individual, and the sequence tested genotypically may not be derived
from only one virus. Ideally, genotypic testing on SGA sequences, the sequences of
clones or NGS sequence data would be a more accurate approach and would provide
a better prediction of whether X4 variants are present or absent in an individual’s viral
population.
A final point worth mentioning, is the handing of multiple sequences for the same
patient. In this regard, only one randomly selected sequence was retained for further
analysis, accounting for approximately 5200 discarded sequences - each potentially
67
 
 
 
 
4. DISCUSSION
representing an outlier sequence. However, each sequence being randomly selected
essentially negates this concern, as the possibility that the chosen sequence - for each
patient with greater than 2 representative sequences - is an outlier would be minimised.
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Chapter 5
Conclusions
This study adds to the limited characterisation of CXCR4-usage in HIV-1 subtype
C. Using a comprehensive, geographically diverse dataset, we find that geno2pheno
(FPR5) is the most accurate approach available for the prediction of coreceptor tropism
in HIV-1 subtype C viral sequences, with an accuracy of 94% (89% sensitivity and 99%
specificity). Coupled with its high accuracy, the ability of geno2pheno to account for
ambiguous nucleotide calls in V3 sequences gives it a distinct advantage over all other
approaches for coreceptor genotyping of sequence data generated from population-
based sequencing. Web C-PSSM, the only tool tested that was designed on subtype C
sequence data, had a slightly lower prediction ability compared to subtype B-trained
geno2pheno.
Based on these findings, we conclude that the geno2pheno coreceptor tool may
be used as a reliable genotypic predictor in clinical settings to establish the viabil-
ity of CCR5-antagonist therapies using drugs such as Maraviroc. At approximately
USD100-200, genotypic sequencing provides a rapid and cost effective alternative to
phenotypic testing, particularly in resource limited areas. The significance of geno-
typic testing is further highlighted when compared to the cost of phenotypic testing,
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with the Trofile assay being undertaken at a cost of approximately USD1500 - an
amount which few individuals can afford in the most severely affected regions of the
world.
Furthermore, we report that in HIV-1 group M subtype C, sequences from dual-
tropic viruses have minimal effect on the performance of genotypic tools and the op-
timal approaches for prediction of CXCR4-usage in sequence from viruses that use
CXCR4 exclusively also perform best at predicting CXCR4-use in dual-tropic viral
variants. Based on this, it appears that viral genotyping of envelope sequences from
subtype C infected individuals is feasible with the correct approach and can be under-
taken with a high degree of confidence that CXCR4-usage will be accurately identified
in both CXCR4-exclusive and dual tropic variants.
In determining HIV-1 subtype C prevalence and patterns of CXCR4-usage, we find
that a switch to CXCR4-usage is seen in subtype C for well over 20 years. A switch
from CCR5 to CXCR4-usage has consistently taken place in subtype C over time, sug-
gesting that CXCR4-usage has not evolved recently.
We find that in our dataset, which constitutes the largest collection of subtype C
sequences, the overall frequency of CXCR4-using sequences seen is not only lower
than the prevalence previously reported for subtype B sequences, but also lower than
found in other studies on subtype C. We report a frequency of 5% for the switch to
CXCR4-usage in subtype C. These observations are important in understanding the
rapid spread of HIV-1 subtype C in the developing world and may have broad implica-
tions for the design of intervention and treatment strategies.
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Table 6.1: Tables detailing the uncorrected numbers of true positives (CXCR4-usage
correctly predicted in CXCR4-using sequences), true negatives (CCR5-usage correctly
predicted in CCR5-using sequences), false positives (CXCR4-usage incorrectly pre-
dicted in CCR5-using sequences) and false negatives (CCR5-usage incorrectly pre-
dicted in CXCR4-using sequences) predicted by each of the approaches. Results are
shown for (A) CXCR4-using sequences, (B) CXCR4-exclusive sequences and (C)
dual-tropic sequences.
A
Method TP TN FP FN
Web PSSM sinsi 44 348 1 14
Web PSSM X4R5 43 338 10 14
Web C-PSSM 52 317 29 6
Geno2Pheno FPR5 50 344 5 6
Geno2Pheno FPR10 50 328 21 6
Geno2Pheno FPR20 51 299 50 5
WetCat C4.5 23 346 3 34
WetCat C4.5 pos.8&12 23 348 1 35
WetCat PART 32 348 1 26
WetCat SVM 36 344 3 21
11/24/25 Charge Rule 38 340 9 20
11/25 Charge Rule 34 347 2 24
Raymond Approach 55 262 82 2
B
Method TP TN FP FN
Web PSSM sinsi 19 348 1 6
Web PSSM X4R5 19 338 10 6
Web C-PSSM 22 317 29 3
Geno2Pheno FPR5 22 344 5 3
Geno2Pheno FPR10 22 328 21 3
Geno2Pheno FPR20 22 299 50 3
WetCat C4.5 10 346 3 15
WetCat C4.5 pos.8&12 10 348 1 15
WetCat PART 13 348 1 12
WetCat SVM 16 344 3 9
11/24/25 Charge Rule 16 340 9 9
11/25 Charge Rule 13 347 2 12
Raymond Approach 25 262 82 0
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C
Method TP TN FP FN
Web PSSM sinsi 25 348 1 8
Web PSSM X4R5 24 338 10 8
Web C-PSSM 30 317 29 3
Geno2Pheno FPR5 28 344 5 3
Geno2Pheno FPR10 28 328 21 3
Geno2Pheno FPR20 29 299 50 2
WetCat C4.5 13 346 3 19
WetCat C4.5 pos.8&12 13 348 1 20
WetCat PART 19 348 1 14
WetCat SVM 20 344 3 12
11/24/25 Charge Rule 22 340 9 11
11/25 Charge Rule 21 347 2 12
Raymond Approach 30 262 82 2
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Table 7.1: Number of HIV-1 subtype C sequences recorded per country.
Country Number of sequences recorded
Georgia 1
Hungary 1
Indonesia 1
Korea (South) 1
Lebanon 1
Latvia 1
Mexico 1
Romania 1
Sudan 1
Thailand 1
Uruguay 1
Vietnam 1
Yemen 1
Argentina 2
Austria 2
Greece 2
Malaysia 2
Nigeria 2
New Zealand 2
Philippines 2
Belarus 3
Estonia 3
Italy 3
Venezuela 3
Gabon 4
Norway 4
Taiwan 4
Rwanda 5
Singapore 5
Gambia 6
Iran 6
Cameroon 7
Cuba 8
Germany 8
Djibouti 8
Finland 8
Guinea-Bissau 8
Myanmar 8
Russian Federation 8
Table continued...
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Table 7.1 continued
Country Number of sequences recorded
Seychelles 8
Spain 9
Bangladesh 11
Belgium 11
Somalia 11
Angola 12
Czech Republic 12
Israel 13
Senegal 13
Fiji 15
Japan 15
Australia 16
Cyprus 17
Great Britain 24
Papua New Guinea 32
Portugal 33
Netherlands 36
Nepal 36
China 38
Denmark 43
France 53
Sweden 89
Congo 90
Uganda 105
United States 105
Kenya 107
Mozambique 110
Burundi 119
Brazil 122
Switzerland 148
Botswana 225
Ethiopia 467
Tanzania 479
Zimbabwe 612
India 1201
South Africa 2265
Malawi 2462
Zambia 2804
Unknown 18
Total: 12121
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RESEARCH ARTICLE Open Access
Appraising the performance of genotyping tools
in the prediction of coreceptor tropism in HIV-1
subtype C viruses
Saleema Crous, Ram Krishna Shrestha and Simon A Travers*
Abstract
Background: In human immunodeficiency virus type 1 (HIV-1) infection, transmitted viruses generally use the CCR5
chemokine receptor as a coreceptor for host cell entry. In more than 50% of subtype B infections, a switch in
coreceptor tropism from CCR5- to CXCR4-use occurs during disease progression. Phenotypic or genotypic
approaches can be used to test for the presence of CXCR4-using viral variants in an individual’s viral population that
would result in resistance to treatment with CCR5-antagonists. While genotyping approaches for coreceptor-
tropism prediction in subtype B are well established and verified, they are less so for subtype C.
Methods: Here, using a dataset comprising V3 loop sequences from 349 CCR5-using and 56 CXCR4-using HIV-1
subtype C viruses we perform a comparative analysis of the predictive ability of 11 genotypic algorithms in their
prediction of coreceptor tropism in subtype C. We calculate the sensitivity and specificity of each of the
approaches as well as determining their overall accuracy. By separating the CXCR4-using viruses into CXCR4-
exclusive (25 sequences) and dual-tropic (31 sequences) we evaluate the effect of the possible conflicting signal
from dual-tropic viruses on the ability of a of the approaches to correctly predict coreceptor phenotype.
Results: We determined that geno2pheno with a false positive rate of 5% is the best approach for predicting
CXCR4-usage in subtype C sequences with an accuracy of 94% (89% sensitivity and 99% specificity). Contrary to
what has been reported for subtype B, the optimal approaches for prediction of CXCR4-usage in sequence from
viruses that use CXCR4 exclusively, also perform best at predicting CXCR4-use in dual-tropic viral variants.
Conclusions: The accuracy of genotyping approaches at correctly predicting the coreceptor usage of V3 sequences
from subtype C viruses is very high. We suggest that genotyping approaches can be used to test for coreceptor
tropism in HIV-1 group M subtype C with a high degree of confidence that they will identify CXCR4-usage in both
CXCR4-exclusive and dual tropic variants.
Keywords: Human immunodeficiency virus, Coreceptor, Chemokine receptors, CXCR4, CCR5, Genotype, Phenotype,
Subtype C
Background
To enable cell entry by HIV, the gp120 glycoprotein,
present in a trimeric arrangement on the surface of a
HIV virion, must first bind to a CD4 receptor on the tar-
get cell [1-3]. This binding induces a conformational
change in the gp120/gp41 trimer complex [4,5] thereby
enabling binding of a chemokine receptor, either CCR5
or CXCR4 [6]. CCR5-tropic viruses are associated with
primary transmission and can persist throughout infec-
tion [6]. In as many as 50% of HIV-1 subtype B infec-
tions, a switch to CXCR4-usage has been observed and
this switch is generally regarded as an indicator of dis-
ease progression [7-10]. Early studies of HIV-1 subtype
C suggested that a switch to CXCR4-usage was less
common in subtype C compared to subtype B [11,12],
however more recent studies have suggested that be-
tween 30-50% of subtype C infected individuals exhibit
a change to CXCR4-usage during disease progression
[13-18].
* Correspondence: simon@sanbi.ac.za
South African National Bioinformatics Institute, University of the Western
Cape, Private Bag X17, Belville 7535, South Africa
© 2012 Crous et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Dual-tropic viruses (R5X4) capable of using either
CCR5 or CXCR4 for host cell entry have been described
[19] as have dual-tropic viruses that, while capable of
using either receptor for cell entry, exhibit preferential
use of either CCR5 (dual-R) or CXCR4 (dual-X) [20,21].
Detecting the presence of dual-tropic viruses in an indi-
vidual’s viral population is difficult however, as a mixed
population of R5 and X4 viruses will be identified as
dual in a population-based phenotyping assay.
Determining the coreceptor usage profile of an indivi-
dual’s viral population has been used as an indicator of
disease progression and in more recent years as an ap-
proach for detecting resistance to CCR5 antagonists
such as maraviroc [22-24]. Phenotypic assays, such as
Monogram Bioscience’s Trofile™ assay [25], are the most
effective means of elucidating the coreceptor tropism of
a viral population. These approaches, however, are ex-
pensive, laborious and unavailable for routine use in all
laboratories [26,27]. Thus, genotyping approaches have
been suggested to be a viable alternative for routine cor-
eceptor tropism testing [28]. While many amino acid
positions throughout gp120 have been suggested to in-
fluence coreceptor affinity and tropism [29-35], the V3
loop appears to be the strongest determinant of corecep-
tor tropism with amino acid mutations affecting V3 net
charge, charge at positions 11, 24 and 25 and glycan
binding patterns all implicated in causing a switch from
CCR5- to CXCR4-usage [36-41].
Early genotypic algorithms predicted the coreceptor
tropism of HIV-1V3 sequences using the properties of
the amino acids at positions 11 and 25 while later algo-
rithms account for various properties of the entire V3
loop [39,40,42-45]. With the exception of C-PSSM [43]
and the Raymond combined 11/25 and net charge rules
[46], all of these approaches have been optimised for
coreceptor tropism prediction in subtype B and show
varying levels of sensitivity at predicting CXCR4-usage
in subtype B [47].
Despite HIV-1 subtype C accounting for almost 60%
of worldwide HIV infections [48], the genetic determi-
nants of the switch in coreceptor use are less-well
understood than in subtype B. Conflicting reports have
been published with some suggesting that these determi-
nants are the same for subtype C as subtype B [46],
while others have presented evidence to the contrary
[43]. Jensen and colleagues developed the only subtype
C specific genotyping tool with a reported sensitivity of
75% [43] while others evaluated the ability of this and
other algorithms trained on subtype B data at correctly
predicting CXCR4-use in subtype C sequence data [46].
They found that the most appropriate approach for pre-
dicting CXCR4-usage in subtype C were C-PSSM and
their combined 11/25 and net charge rule [46]. When
specificity was considered, however, Raymond and
colleagues approach was significantly better than C-
PSSM (96.4% versus 81.8%). The dataset used in this
study, however, did not represent the entire spectrum of
HIV-1 subtype C diversity in that it had a limited num-
ber of phenotyped sequences (55 R5 and 15 X4
sequences) collected from only two countries (Malawi
and France).
In this study we have collated a large dataset consist-
ing of all obtainable subtype C sequences with experi-
mentally verified coreceptor tropism and used this to
evaluate the performance of various genotyping tools at
accurately predicting CXCR4-usage in HIV-1 subtype C.
Further, we determine the effect of sequences from dual-
tropic viruses on the sensitivity of genotyping methods.
Results and discussion
In total 731 HIV-1 group M subtype C V3 sequences
with experimentally verified coreceptor tropism were
retrieved. Only one representative sequence for each in-
dividual was retained reducing the total number of
sequences to 405. The final analysis dataset (available on
request) contained sequences from 349 CCR5-using and
56 CXCR4-using viruses. Sequences from CXCR4-using
viruses were further separated into R5X4 (dual-tropic)
and CXCR4-exclusive viruses with 31 and 25 sequences,
respectively, comprising these datasets.
The coreceptor usage of every sequence in each of the
datasets was predicted using all of the genotyping
approaches. 23 of the sequences tested contained at least
one ambiguous nucleotide position. Geno2pheno is the
only one of the tools tested that is capable of accounting
for ambiguous positions in its genotypic predictions
[44]. To assess all of the other approaches, we translated
the nucleotide sequences into all the possible combina-
tions of amino acid sequences and if one or more of
these translated sequences was predicted as CXCR4-
using, the genotyping call for the original sequence was
taken as X4. For each of the 23 sequences, all possible
translations of the sequence had the same coreceptor
tropism prediction for each method. Thus, in this data,
ambiguous positions did not affect the genotypic predic-
tions. However, in many cases the presence of ambigu-
ous nucleotide calls, particularly within the codons
encoding for amino acid positions 11, 24 and 25, would
substantially reduce the ability of approaches to correctly
predict coreceptor usage [44]. Thus, the ability to ac-
count for ambiguous nucleotide positions in geno2pheno
gives it a distinct advantage over all of the other
approaches tested here.
The sensitivity of each of the tested approaches at pre-
dicting X4 viruses in the CXCR4-using dataset (dual
tropic and CXCR4-exclusive combined) varied widely
from 40-97% (Table 1 and Figure 1). The method by
Raymond and colleagues performed best with 97%
Crous et al. BMC Infectious Diseases 2012, 12:203 Page 2 of 8
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sensitivity while Geno2pheno (FPR20) and C-PSSM
exhibited high sensitivities greater than 90%. Two var-
iants of the wetcat package, C4.5 and C4.5 with p8-p12,
performed most poorly with sensitivities of 40%,
consistent with previous observations on both subtype B
and non-B subtypes [46,47,49].
While predicting CXCR4-usage with high accuracy is
important, the ability to correctly identify R5 variants as
CCR5-using is equally as important in reducing the
amount of false positives that would result in incorrect
clinical interpretations. Thus, we also calculated the spe-
cificity (proportion of CCR5-tropic viruses correctly pre-
dicted as R5) of each approach. All approaches
performed well with three having 100% specificity, eight
having specificity greater than 90% and geno2pheno
(FPR20) and Raymond exhibiting lower specificity of
86% and 76% respectively (Table 1 and Figure 1). These
high specificity values are consistent with previous
observations in both HIV-1 subtype B and non-B sub-
types that all approaches, in general, are better at cor-
rectly predicting CCR5-usage than CXCR4-usage
[22,43,46,47,49].
Raymond and colleagues had previously evaluated nine
of the 13 approaches studied here using a smaller, geo-
graphically limited subtype C dataset comprising 55 R5
and 15 X4 viral sequences sampled from Malawi and
France [46]. They reported that the optimal approach
for subtype C genotyping was a combination of the 11/
25 and net charge rules with sensitivity and specificity
for CXCR4-usage prediction in subtype C of 93.3%
and 96.4% respectively. Using the larger and more
Table 1 Performance of genotyping approaches at
predicting CXCR4-usage in viral sequences from
individuals infected with HIV-1 group M subtype C
Method CXCR4-using sensitivity (%) Specificity
PSSM_sinsi 76 100
PSSM_X4R5 75 97
C-PSSM 90 92
Geno2Pheno_FPR5 89 99
Geno2Pheno_FPR10 89 94
Geno2Pheno_FPR20 91 86
WetCat_C4.5 40 99
WetCat_C4.5 pos. 8&12 40 100
WetCat_PART 55 100
WetCat_SVM 63 99
11/24/25 68 97
11/25 60 99
Raymond 97 76
Sensitivity corresponds to the ability of the approach to predict CXCR4-use,
while specificity corresponds to the ability to correctly predict CCR5-use.
Figure 1 Performance of each of the genotyping algorithms in predicting CXCR4-usage. Sensitivity for both the CXCR4-using and CXCR4-
exclusive datasets was calculated as the number of viral sequences predicted as CXCR4-using divided by the total number of CXCR4-using or
CXCR4-exclusive sequences tested. Specificity corresponds to the number of CCR5-using viruses predicted as R5 divided by the total number of
CCR5-using viral sequences evaluated.
Crous et al. BMC Infectious Diseases 2012, 12:203 Page 3 of 8
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geographically diverse dataset studied here, we esti-
mate sensitivity of 97% and a specificity of 76% for
this approach. Compared to the other approaches
tested, however, Raymond’s method is not the opti-
mal approach. While it does show the highest sensitiv-
ity, it also has the lowest specificity of all the
approaches tested (Table 1). For the other approaches
we find that sensitivity increases by as much as 22% for
five of the approaches relative to the Raymond study,
while the sensitivity of PSSMsinsi, PSSMX4R5 and C-
PSSM drops by 4%, 5% and 3% respectively. We suggest
that the weaker performance on our comprehensive
subtype C dataset of the combined 11/25 and net charge
rule proposed by Raymond and colleagues is most likely
an artifact of the limited sample size/diversity in their
dataset that is not present in the larger dataset studied
here. In describing C-PSSM, Jensen and colleagues used
a dataset consisting 228 R5 sequences and 51 X4
sequences (from 200 and 20 subjects respectively) [43]
and reported a sensitivity of 75%, substantially less than
the 90% sensitivity reported here, with comparable spe-
cificities of 94% and 92%.
While some methods are extremely sensitive at cor-
rectly predicting CXCR4-use, the optimum approach for
clinical implementation also needs to be highly specific
in correctly identifying viruses that do not use CXCR4.
Thus, we have calculated an accuracy score for each of
the approaches tested that takes into account an
approach’s sensitivity and specificity (Table 2). For the
CXCR4-using dataset, we find that three of the 13
approaches tested have an accuracy of 90% or greater at
predicting coreceptor usage in HIV-1 group M subtype
C viral sequences with geno2pheno (FPR5) being the
most accurate of all approaches tested with an accuracy
of 94% (89% sensitivity and 99% specificity, Table 2).
Two variants of the wetcat package, C4.5 and C4.5 with
p8-p12, both perform poorest with accuracy scores of
70% (Table 2).
Dual-tropic viruses are a unique class of viruses in that
they can enter host cells using either CCR5 or CXCR4
chemokine receptors, however, some dual-tropic viruses
can exhibit preferential use of one of these [19-21]. From
a clinical perspective, it is imperative that genotyping
approaches correctly identify the CXCR4-using capabil-
ities of dual-tropic viruses. Genotyping algorithms have
been shown to vary widely in their predictive ability of
CXCR4-usage in subtype B dual-tropic viruses [50]. In
general, approaches were observed to underestimate the
frequency of CXCR4-usage in dual tropic viruses [50].
Thus, we sought to investigate the effect of dual-tropic
viruses on the accuracy of each of the genotyping
approaches tested. The CXCR4-using viruses were sepa-
rated into CXCR4-exclusive and dual-tropic viral
sequences and the accuracy of each of the approaches at
correctly predicting coreceptor tropism was calculated
(Table 2). When dual-tropic sequences are excluded, the
accuracy of three of the approaches increases minimally,
with four methods showing no change in accuracy and
six showing a slight decrease of 1% in accuracy (Table 2).
Similarly, when the dual-tropic viruses were studied sep-
arately there was minimal effect on the accuracy of each
of the approaches (Table 2). There was significant vari-
ability in the ability of the approaches to accurately pre-
dict CXCR4-usage in dual-tropic viruses, ranging from
40% (wetcat C4.5 with p8-p12) to 94% (Geno2pheno
FPR20) of sequences from dual-tropic viruses predicted
as CXCR4-using (Figure 2). It appears that, in subtype C
at least, the ability of approaches to predict CXCR4-
usage in dual tropic viruses directly correlates with their
ability to predict CXCR4-usage in CXCR4-exclusive
viruses. Such an observation does not appear to hold
true in subtype B, however, where some methods with
high sensitivity for prediction of CXCR4 viruses in sub-
type B [47], show low accuracy for the prediction of
CXCR4-usage in subtype B dual-tropic viral sequences
[50]. Geno2pheno, however, does show high accuracy
(90%) for the prediction of CXCR4-usage in subtype B
dual-tropic viruses [50].
Conclusion
Using a comprehensive, geographically diverse dataset,
we find that geno2pheno (FPR5) is the most accurate ap-
proach for the prediction of coreceptor tropism in HIV-
1 subtype C viral sequences. Coupled with it’s high ac-
curacy, the ability of geno2pheno to account for
Table 2 Accuracy of genotyping approaches at correctly
predicting coreceptor tropism
Method CXCR4-using
accuracy
CXCR4-exclusive
accuracy
R5X4
accuracy
PSSM_sinsi 88 88 88
PSSM_X4R5 86 87 86
C-PSSM 91 90 91
Geno2Pheno_FPR5 94 93 94
Geno2Pheno_FPR10 92 91 92
Geno2Pheno_FPR20 88 87 90
WetCat_C4.5 70 70 70
WetCat_C4.5 pos. 8&12 70 70 70
WetCat_PART 77 76 79
WetCat_SVM 81 82 81
11/24/25 81 81 82
11/25 79 76 82
Raymond 86 88 85
Accuracy scores are presented for a combined dataset containing CXCR4-using
viruses (both CXCR4-exclusive and dual-tropic viruses) as well as separately for
the CXCR4-exclusive and dual-tropic viral sequences.
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approach was not designed to account for ambiguous
nucleotide positions, all possible combinations of amino
acid sequences were output and a worst-case scenario
approach was employed whereby if one of these trans-
lated sequences was predicted as CXCR4-using, the
genotyping call for the original sequence was taken as
X4.
Viral sequences were separated into three distinct cat-
egories (R5, X4 and R5X4) based upon their experimen-
tally verified viral phenotype. Dual-tropic and CXCR4-
tropic viruses were studied both separately and together
(as CXCR4-using) in order to determine the affect of the
conflicting signal of dual-tropic viruses on sensitivity
estimates. The sensitivity of each approach for CXCR4
prediction was calculated as the number of predicted X4
viruses in the CXCR4-using dataset divided by the total
number of sequences in the CXCR4-using dataset. The
specificity of each approach for CXCR4 prediction was
calculated as the number of predicted R5 viruses in the
CCR5-using dataset divided by the total number of
sequences in the CCR5-using dataset. The same method
was used to calculate the sensitivity and specificity of
each genotyping method on the CXCR4-exclusive and
dual-tropic datasets.
Further, an overall accuracy score for each of the
approaches used was calculated using:
TP þ TN
TP þ TN þ FP þ FN
where, for the CXCR4-using dataset, TP corresponds to
the number of CXCR4-using sequences predicted as
CXCR4-using, TN the number of R5 sequences pre-
dicted as CCR5-using, FP the number of R5 sequences
predicted as CXCR4-using and FN the number of
CXCR4-using sequences predicted as CCR5-using. For
the CXCR4-exclusive dataset the TP and FN values
were calculated only for sequences phenotypically
determined to exclusively use CXCR4. For each cal-
culation we normalized the TP and FN values rela-
tive to the TN and FP values to account for the
disproportionate number of sequences representing
the positive (CXCR4-using or CXCR4-exclusive) and
negative (CCR5) datasets (see Additional file 1: Table
S1 for the uncorrected values).
Additional file
Additional file 1: Table S1. Tables detailing the uncorrected numbers
of true positives (CXCR4-usage correctly predicted in CXCR4-using
sequences), true negatives (CCR5-usage correctly predicted in CCR5-using
sequences), false positives (CXCR4-usage incorrectly predicted in CCR5-
using sequences) and false negatives (CCR5-usage incorrectly predicted
in CXCR4-using sequences) predicted by each of the approaches. Results
are shown for (A) CXCR4-using sequences, (B) CXCR4-exclusive sequences
and (C) dual-tropic sequences.
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